421 related articles for article (PubMed ID: 32042344)
1. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
[TBL] [Abstract][Full Text] [Related]
2. Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner.
Papageorgis P; Polydorou C; Mpekris F; Voutouri C; Agathokleous E; Kapnissi-Christodoulou CP; Stylianopoulos T
Sci Rep; 2017 Apr; 7():46140. PubMed ID: 28393881
[TBL] [Abstract][Full Text] [Related]
3. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
4. Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy.
Mpekris F; Papageorgis P; Polydorou C; Voutouri C; Kalli M; Pirentis AP; Stylianopoulos T
J Control Release; 2017 Sep; 261():105-112. PubMed ID: 28662901
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
6. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
Chen Q; Xu L; Chen J; Yang Z; Liang C; Yang Y; Liu Z
Biomaterials; 2017 Dec; 148():69-80. PubMed ID: 28968536
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
8. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
[TBL] [Abstract][Full Text] [Related]
9. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
11. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis.
Mpekris F; Panagi M; Voutouri C; Martin JD; Samuel R; Takahashi S; Gotohda N; Suzuki T; Papageorgis P; Demetriou P; Pierides C; Koumas L; Costeas P; Kojima M; Ishii G; Constantinidou A; Kataoka K; Cabral H; Stylianopoulos T
Adv Sci (Weinh); 2021 Feb; 8(3):2001917. PubMed ID: 33552852
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
13. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models.
Panagi M; Mpekris F; Chen P; Voutouri C; Nakagawa Y; Martin JD; Hiroi T; Hashimoto H; Demetriou P; Pierides C; Samuel R; Stylianou A; Michael C; Fukushima S; Georgiou P; Papageorgis P; Papaphilippou PC; Koumas L; Costeas P; Ishii G; Kojima M; Kataoka K; Cabral H; Stylianopoulos T
Nat Commun; 2022 Nov; 13(1):7165. PubMed ID: 36418896
[TBL] [Abstract][Full Text] [Related]
14. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
[TBL] [Abstract][Full Text] [Related]
15. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.
Zhao Q; He X; Qin X; Liu Y; Jiang H; Wang J; Wu S; Zhou R; Yu C; Liu S; Zhang H; Tian M
Front Immunol; 2022; 13():938439. PubMed ID: 35812418
[TBL] [Abstract][Full Text] [Related]
17. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
[TBL] [Abstract][Full Text] [Related]
19. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
20. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]